Wion Web Desk

Kashmir Valley likely to receive fresh spell of snowfall today; dry weather forecast till November 9

"That run-out by Rohit changed the momentum": Gill reflects on India's 5-wicket win in 1st ODI vs NZ

Houthis put a price on peace with Saudi: $51 billion and recognition as Yemen's rulers - Report

Virat Kohli turns 38: 5 records that define his cricketing legacy

Trump's 'best guy' Pete Hegseth on the chopping block? Why Republicans are now turning against him after midterms disaster

After Microsoft, Google expands voluntary exit programme to employees in 5 countries amid AI spending

Nithya Raman wins LA mayoral race, becomes city's first Asian-American mayor

First handshake? Radio signal with all hallmarks of alien technology detected in China

Chandigarh couple at centre of fresh US sanctions over helping Iran evade oil sanctions

US midterms: What went wrong for Trump? | Gravitas

'I am more Indian than Arab': Abdul El-Sayed on his Indian-origin wife

Israel's Ra'am party backs Gadi Eisenkot to lead next government after meeting with Herzog

Ramayana: Part 1 movie review: Yash’s powerhouse performance and jaw-dropping VFX fuel Nitesh Tiwari's epic

Doomsday warning? Why governments are warning people to stockpile emergency supplies for 72 hours

US Midterms 2026: Abdul El-Sayed wins Michigan race, becomes first Muslim American to be elected to US Senate

Keran Heritage Centre to give new impetus to border tourism in North Kashmir

US midterms: Did Trump lose young voters, women and minorities? Here's how Americans voted

Watch: Ilhan Omar breaks into a dance after securing fifth-term victory amid long-running Trump feud

Dirty war ahead? Trump has options of renewed strikes on Iran or letting it rot, but officials are divided after US midterms rout

Ueno Bank crisis: Why are millions protesting as Paraguay’s president faces impeachment?

Saudi Arabia rolls over $3 billion financing to Pakistan as $10 billion US backstop fades

'Habibi, there's a delicious irony': What the word Abdul El-Sayed used on JD Vance actually means | US Midterms 2026

‘Iran handed Trump political defeat after strategic ones,’ says security chief Mohsen Rezaei

Ashwin shares reasons for Bhuvneshwar's struggle in NZ T20Is, says his 'chapter is maybe closed'

Who is Abdul El-Sayed’s wife Sarah Jukaku and what is her Indian connection?

US Midterms 2026: Pooja Sethi defeats bigotry, makes history as first Hindu, Indian-American woman elected to Texas Legislature

Indian Army marks Battle of Shalateng Day with veterans’ rally, educational outreach at Sharifabad

Florida shooting: Two dead, including suspect, after gunfire at Citibank's Tampa-area complex

Ramayana Part 1 X reviews: Netizens hail Ranbir Kapoor-Yash's mythological epic, call it a 'monumental cinematic masterpiece'

From Texas to South Carolina: How Democrats stormed Republican strongholds to redraw America's political map in US midterms 2026

Mahadev app co-founder Ravi Uppal arrested in Dubai days after kingpin Sourabh Chandrakar’s extradition

‘Dialled wrong number in season of dharna, go protest’: CJI’s quip on plea seeking rotation of SC-ST reserved seats

Hyderabad, Nov (IANS) Vaccine maker Bharat Biotech on Monday announced that it has commenced Phase-3 trials of Covaxin, India`s first indigenous vaccine for Covid-19.
 
The Phase-3 trials, which involve 26,000 volunteers across India, are being conducted in partnership with the Indian Council of Medical Research (ICMR). 
This is India`s first Phase-3 efficacy study for a Covid-19 vaccine, and the largest Phase-3 efficacy trial ever conducted in India, the Hyderabad-based company said. 
Trial volunteers will receive two intramuscular injections approximately 28 days apart. Participants will be randomly assigned to receive Covaxin or a placebo. The trial is double blinded, such that the investigators, the participants and the company will not be aware of who is assigned to which group. 
The trials are being conducted at 22 institutes in India including the All India Institute of Medical Sciences (AIIMS), the Guru Tegh Bahadur Hospital (both New Delhi), the Aligarh Muslim University, the Grant Government Medical College and Sir J.J. Group of Hospitals, Lokmanya Tilak Municipal General Hospital and Medical College (Sion Hospital) (all three Mumbai), the ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, the Directorate of Public Health and Preventive Medicine, Chennai and King George Hospital, Vizag. 
Participating volunteers, who undergo vaccination in the Phase-3 trials, will be monitored to detect occurrence of Covid-19. 
Covaxin has been evaluated in about 1,000 subjects in Phase-1 and Phase-2 clinical trials, with promising safety and immunogenicity data. Volunteers who wish to participate in this trial should be adults over 18 years of age. 
Covaxin by Bharat Biotech is developed in collaboration with the ICMR - National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech`s BSL-3 (Bio-Safety Level 3) bio containment facility. 
Covaxin is a highly purified and inactivated vaccine, manufactured in a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied. 
"The development and clinical evaluation of Covaxin marks a significant milestone for vaccinology in India, for a novel vaccine. It is important for Indian companies to innovate and develop indigenous vaccines, especially during a pandemic. Covaxin has garnered interest from several countries worldwide for supplies and introduction," said Suchitra Ella, Joint Managing Director of Bharat Biotech. 
--IANS 
ms/vd

 India News News

 wionews.com

Hyderabad, Nov (IANS) Vaccine maker Bharat Biotech on Monday announced that it has commenced Phase-3 trials of Covaxin, India`s first indigenous vaccine for Covid-19. The Phase-3 trials, which involve 26,000 volunteers across India, are being conducted in partnership with the Indian Council of Medical Research (ICMR). This is India`s first Phase-3 efficacy study for a Covid-19 vaccine, and the largest Phase-3 efficacy trial ever conducted in India, the Hyderabad-based company said. Trial volunteers will receive two intramuscular injections approximately 28 days apart. Participants will be randomly assigned to receive Covaxin or a placebo. The trial is double blinded, such that the investigators, the participants and the company will not be aware of who is assigned to which group. The trials are being conducted at 22 institutes in India including the All India Institute of Medical Sciences (AIIMS), the Guru Tegh Bahadur Hospital (both New Delhi), the Aligarh Muslim University, the Grant Government Medical College and Sir J.J. Group of Hospitals, Lokmanya Tilak Municipal General Hospital and Medical College (Sion Hospital) (all three Mumbai), the ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, the Directorate of Public Health and Preventive Medicine, Chennai and King George Hospital, Vizag. Participating volunteers, who undergo vaccination in the Phase-3 trials, will be monitored to detect occurrence of Covid-19. Covaxin has been evaluated in about 1,000 subjects in Phase-1 and Phase-2 clinical trials, with promising safety and immunogenicity data. Volunteers who wish to participate in this trial should be adults over 18 years of age. Covaxin by Bharat Biotech is developed in collaboration with the ICMR - National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech`s BSL-3 (Bio-Safety Level 3) bio containment facility. Covaxin is a highly purified and inactivated vaccine, manufactured in a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied. "The development and clinical evaluation of Covaxin marks a significant milestone for vaccinology in India, for a novel vaccine. It is important for Indian companies to innovate and develop indigenous vaccines, especially during a pandemic. Covaxin has garnered interest from several countries worldwide for supplies and introduction," said Suchitra Ella, Joint Managing Director of Bharat Biotech. --IANS ms/vd

India''s first vaccine candidate, Covaxin''s Phase-3 trials begin

Hyderabad, Nov (IANS) Vaccine maker Bharat Biotech on Monday announced that it has commenced Phase-3 trials of Covaxin, India`s first indigenous vaccine for Covid-19.

India''s first vaccine candidate, Covaxin''s Phase-3 trials begin

About the Author

Wion Web Desk

Wion Web Desk